Oncophage clinical trials
Also written HSPPC-96 and vitespen.
How each study uses oncophage is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1999 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 8
Agenus Inc. (4) · University of California, San Francisco (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Alliance for Clinical Trials in Oncology (1) · Rabih Said (1)
Studies
Open first, then newest update. How each study uses oncophage is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)TerminatedPhase 2National Cancer Institute (NCI)NCT03018288Written as HSPPC-96How we know
- Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) VaccineTerminatedPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT02722512Written as Heat Shock Protein Peptide Complex-96 (HSPPC-96)How we know
- Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryTerminatedPhase 2Alliance for Clinical Trials in OncologyNCT01814813Written as HSPPC-96How we know
- Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of RecurrenceTerminatedPhase 2Agenus Inc.NCT01147536Written as HSPPC-96How we know
- GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive GliomaCompletedPhase 1/2University of California, San FranciscoNCT00293423Written as HSPPC-96How we know
- HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBMCompletedPhase 2University of California, San FranciscoNCT00905060Written as HSPPC-96How we know
- Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaWithdrawnPhase 1/2Rabih SaidNCT02452281Written as HSPPC-96How we know
- Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00003025Written as vitespenHow we know
- Vaccine Therapy in Treating Patients With Recurrent Soft Tissue SarcomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00005628Written as vitespenHow we know
- Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedPhase 3Agenus Inc.NCT00039000Written as HSPPC-96 or OncophageHow we know
- Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney CancerTerminatedPhase 3Agenus Inc.NCT00126178Written as HSPPC-96How we know
- Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung CancerCompletedPhase 2Agenus Inc.NCT00098085Written as HSPPC-96How we know
Codes
What other systems call oncophage · ClinicalTrials.gg INT016733
- UNII (FDA) H3598Y1TLJVITESPENConfirmed FDA, Wikidata
- Wikidata Q7092116oncophageConfirmed FDA, Wikidata
- DrugBank DB06400One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H3598Y1TLJ | VITESPEN | Confirmed FDA, Wikidata |
| Wikidata | Q7092116 | oncophage | Confirmed FDA, Wikidata |
| DrugBank | DB06400 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.